CDT Equity closed at $0.44 on Nov 12, down 13.10%, within 0.0% of its 52-week closing low. Volume of 523.2K shares was 0.03× its 20-day average (below normal).
Split-adjusted performance: -90.8% over one month, -100.0% over six months, -100.0% over one year.
Short interest was 116.8K shares at the Oct 30 settlement, down 9.8% from the prior report (17.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 419 companies (100 = best)
Industry medians: 6-month return −26.6%, revenue growth +10.0%, net margin −36.2%, P/E 17.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CDTCDT Equity | $0.4432 | −13.10% | −100.0% | — | — | — | $451.1K | |
| DCOYDecoy Therapeutics | $1.06 | −3.21% | −76.7% | — | −1042.8% | — | $691.2K | Compare |
| LABTLakewood-Amedex Biotherapeutics | $0.3592 | −9.06% | — | — | — | — | $851.2K | Compare |
| GOVXGeoVax Labs, Inc. New | $2.04 | −5.56% | −93.3% | −100.0% | — | — | $858.7K | Compare |
| MTNBMatinas BioPharma Holdings | $0.9184 | −1.25% | −89.3% | — | — | — | $899.6K | Compare |
| NXTSNexentis Technologies | $2.01 | −12.61% | — | — | — | — | $955.0K | Compare |
| VBIOValion Bio | $0.5087 | +1.16% | — | — | — | — | $1.1M | Compare |
| ARTLArtelo Biosciences | $2.10 | −4.55% | −90.0% | — | — | — | $1.2M | Compare |
| ELABPMGC Holdings | $1.59 | +0.63% | −92.3% | — | −225.1% | — | $1.3M | Compare |
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
